Pacira Pharmaceuticals Inc. (PCRX) Tops Q2 EPS by 7c; Reaffirms Outlook

Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) reported Q2 EPS of ($0.51), $0.07 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $3.5 million.

Reaffirms outlook.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• Ford reports Q2 sales dip as SUVs and F-Series drive retail share
• Pacira BioSciences to sell iovera° unit to Zimmer Biomet for up to $140M